Arcus Biosciences, Inc.
For the period ended Sep 30, 2025. Filed Oct 28, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Oct 28, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Rule 10b5-1 Trading Arrangements
Theadoption, modification ortermination of contracts, instructions or written plans for the purchase or sale of our securities by our Section 16 officers and directors for the three months ended September 30, 2025, which are intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act, were as follows:
| Name and Title | Action | Date | Total Shares to be Sold | Expiration Date |
|---|---|---|---|---|
| Robert C. Goeltz IIChief Financial Officer | Adoption | September 10, 2025 | 50,138 | January 29, 2027 |
| Juan JaenPresident | Adoption | August 8, 2025 | 265,993 | November 13, 2026 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.